<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S2055 IS: Medical Countermeasure Innovation Act of 2015</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2015-09-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>114th CONGRESS</congress><session>1st Session</session>
		<legis-num>S. 2055</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20150917">September 17, 2015</action-date>
			<action-desc><sponsor name-id="S300">Mr. Burr</sponsor> (for himself and <cosponsor name-id="S309">Mr. Casey</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Public Health Service Act and the Federal Food, Drug, and Cosmetic Act with respect to
			 national health security.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medical Countermeasure Innovation Act of 2015</short-title></quote>.</text>
		</section><section id="id36594527D3104B0EB4645EC37492FEF2"><enum>2.</enum><header>Medical countermeasure guidelines</header>
 <subsection id="id95377F8B0B48413D80CFD4871F91E800"><enum>(a)</enum><header>Strategic national stockpile and security countermeasure procurements</header><text>Section 319F–2 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-6b">42 U.S.C. 247d–6b</external-xref>) is amended—</text> <paragraph id="id0F81440234FB43C18F9BF424E63E8356"><enum>(1)</enum><text>in subsection (a), by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="id021F9EF3B03B4505A4ECB19333A221E9" style="OLC">
 <paragraph id="idA3F2F4A74ABA408A98D49CEC35530CE2"><enum>(3)</enum><header>Utilization guidelines</header><text>The Secretary shall ensure timely and accurate recommended utilization guidelines for qualified countermeasures (as defined in section 319F–1), qualified pandemic and epidemic products (as defined in section 319F–3), and security countermeasures (as defined in subsection (c)), including for such products in the stockpile.</text>
						</paragraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </paragraph><paragraph id="idA6A3551073F449AF8F124BC7990D95B4"><enum>(2)</enum><text>in subsection (g)—</text> <subparagraph id="idC92EAB0CAD574628A23D7FA3F2BC6850"><enum>(A)</enum><text>by amending paragraph (4) to read as follows:</text>
						<quoted-block display-inline="no-display-inline" id="idF891EABAB7C84061A9870E37F4256A84" style="OLC">
 <paragraph id="id2290254A05ED42F9977CF59F07A116CD"><enum>(4)</enum><header>Report on security countermeasure procurement</header><text>Not later than March 1 of each year in which the Secretary determines that the amount of funds available for procurement of security countermeasures is less than $1,500,000,000, the Secretary shall submit to the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives a report detailing the amount of such funds available for procurement and the impact such amount of funding will have—</text>
 <subparagraph id="ID8819B809129C4DDBBC26BA3E5F7B08CB"><enum>(A)</enum><text>in meeting the security countermeasure needs identified under this section; and</text> </subparagraph><subparagraph id="ID8FC586E57CFA4AB88B12436FD191DAB1"> <enum>(B)</enum> <text>on the annual Public Health Emergency Medical Countermeasures Enterprise and Strategy Implementation Plan (pursuant to section 2811(d)).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
					</subparagraph></paragraph></subsection></section><section id="idC5C7B822359E493B878C644EF41229E8"><enum>3.</enum><header>Clarification on BARDA contracting authority</header>
 <subsection id="id7E6C904E88E94F6C9D36D8C16F2CED18"><enum>(a)</enum><header>In general</header><text>Section 319F–2(g) of the Public Health Service Act (42 U.S.C. 247d–6b(g)) is amended by adding at the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="id0B0B7CF838A8463398CDEF2C22CF06DD" style="OLC">
 <paragraph id="idD1A76D849A7F4EDFB17ABE2FCA07FDE7"><enum>(5)</enum><header>Clarification on contracting authority</header><text>The Secretary, acting through the Director of the Biomedical Advanced Research and Development Authority, shall carry out the programs funded by the special reserve fund (for the procurement of security countermeasures under subsection (c) and for carrying out section 319L), including the execution of procurement contracts, grants, and cooperative agreements pursuant to this section and section 319L.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="id1D7EB2D55BDF4F839F2A8CCC5F085F2B"><enum>(b)</enum><header>BARDA contracting authority</header><text>Section 319L(c)(3) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/247d-7c">42 U.S.C. 247d–7c</external-xref>) is amended by inserting <quote>, including the execution of procurement contracts, grants, and cooperative agreements pursuant to this section</quote> before the period.</text>
 </subsection></section><section id="id6835A2E32D0F4248B0B55DCE8BA43EC5"><enum>4.</enum><header>Countermeasures budget plan</header><text display-inline="no-display-inline">Section 2811(b)(7) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/300hh-10">42 U.S.C. 300hh–10(b)(7)</external-xref>) is amended—</text>
 <paragraph id="id5594E0B2E38C4780BC7562F1A772AAA3"><enum>(1)</enum><text>by striking the first sentence and inserting <quote>Develop, and update not later than March 1 of each year, a coordinated 5-year budget plan based on the medical countermeasure priorities described in subsection (d), including with respect to chemical, biological, radiological, and nuclear agent or agents that may present a threat to the Nation, including such agents that are novel or emerging infectious diseases, and the corresponding efforts to develop qualified countermeasures (as defined in section 319F–1), security countermeasures (as defined in section 319F–2), and qualified pandemic or epidemic products (as defined in section 319F–3) for each such threat.</quote>;</text>
 </paragraph><paragraph id="idEFA6486A3E22460C8CDABD02682E61CA"><enum>(2)</enum><text>in subparagraph (C), by striking <quote>; and</quote> and inserting a semicolon;</text> </paragraph><paragraph id="idC7F2055E2BD347659569223FB94F6D4A"><enum>(3)</enum><text>in subparagraph (D), by striking <quote>to the appropriate committees of Congress upon request.</quote> and inserting <quote>, not later than March 15 of each year, to the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives; and</quote>; and</text>
 </paragraph><paragraph id="id08FE4BD8F7874775B8B2D1721C5D6265"><enum>(4)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="id26F2A27096BB46818FE24173C3067F4F" style="OLC"> <subparagraph id="idD5F926316FF64C82B94E920392E8AFA8"><enum>(E)</enum><text>not later than March 15 of each year, be made publicly available.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></section><section id="id4A456E5AAB164CBFBC1B35F442860B44"><enum>5.</enum><header>Prioritizing the animal rule guidance</header><text display-inline="no-display-inline">Section 565(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-4">21 U.S.C. 360bbb–4(c)</external-xref>) is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="id91B7BF04D2E242DBA747A7284174AEE6" style="OLC">
 <paragraph id="id914C87CB7FD44F6BBC23D29D539130A9"><enum>(3)</enum><header>Written explanation</header><text>The Secretary shall provide to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a written explanation, not later than the last day of each month after the date of enactment of the <short-title>Medical Countermeasure Innovation Act of 2015</short-title> in which the Secretary fails to finalize such guidance, for why the Secretary has failed to finalize the guidance as required by this subsection.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </section><section id="id648E5AAC6A1D47A4B137ADFB9C420B83"><enum>6.</enum><header>Streamlining the project bioshield procurement process</header><text display-inline="no-display-inline">Section 319F–2(c) of the Public Health Service Act (42 U.S.C. 247d–6b(c)) is amended—</text> <paragraph id="ida56633c53fe642f584acad7d821c082b"><enum>(1)</enum><text>in paragraph (4)(A)(ii), by striking <quote>make a recommendation under paragraph (6) that the special reserve fund as defined in subsection (h) be made available for the procurement of such countermeasure</quote> and inserting <quote>make available the special reserve fund as defined in subsection (h) for procurement of such countermeasure, as applicable</quote>;</text>
 </paragraph><paragraph id="id64ff2ba6a0af44d2a6a277a4571fe91d"><enum>(2)</enum><text>in paragraph (6)—</text> <subparagraph id="idb3ba62a7821d4da4978bdb7a47d945fc"><enum>(A)</enum><text>by striking subparagraphs (A), (B), and (E);</text>
 </subparagraph><subparagraph id="id9997DED4F5784243BF340C020D0F63A4"><enum>(B)</enum><text>by redesignating subparagraphs (C) and (D) as subparagraphs (A) and (B), respectively;</text> </subparagraph><subparagraph id="id1f9873c5ab6b4c988b298a8ed40b43d4"><enum>(C)</enum><text>by amending subparagraph (A), as so redesignated, to read as follows:</text>
					<quoted-block display-inline="no-display-inline" id="id2EAD99AAD3EA4C67846C125EB664D51F" style="OLC">
 <subparagraph id="id1FC63B3CE6A14E24B53283C89E102BC6"><enum>(A)</enum><header>Notice to appropriate congressional committees</header><text>The Secretary shall notify the Committee on Appropriations and the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Appropriations and the Committee on Energy and Commerce of the House of Representatives of each decision to make available the special reserve fund as defined in subsection (h) for procurement of a security countermeasure, including, where available, the number of, the nature of, and other information concerning potential suppliers of such countermeasure, and whether other potential suppliers of the same or similar countermeasures were considered and rejected for procurement under this section and the reasons therefore.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph><subparagraph id="id7eb8d2792b0145918a772761ba97fe94"><enum>(D)</enum><text>in the heading, by striking <quote><header-in-text level="paragraph" style="OLC">Recommendation for president's approval</header-in-text></quote> and inserting <quote><header-in-text level="paragraph" style="OLC">Recommendations for procurement</header-in-text></quote>; and</text> </subparagraph></paragraph><paragraph id="id7065333c87f244beb264ab25f7588948"><enum>(3)</enum><text>in paragraph (7)—</text>
 <subparagraph id="id669f36910ed94fafb362a1c56f0bccda"><enum>(A)</enum><text>by striking subparagraph (A);</text> </subparagraph><subparagraph id="id657ae0443fd34ab5ace7cada4d986493"><enum>(B)</enum><text>by striking subparagraph (B) and inserting the following:</text>
					<quoted-block display-inline="no-display-inline" id="id180dc62d0fbb480fa1b2dd5364139671" style="OLC">
 <subparagraph id="id0f77361b54664fc5b1a1945990bbffab"><enum>(A)</enum><header>Payments from special reserve fund</header><text>The special reserve fund as defined in subsection (h) shall be available for payments made by the Secretary to a vendor for procurement of a security countermeasure in accordance with the provisions of this paragraph.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph><subparagraph id="id02011e005b2041069c383e4eb7531772"><enum>(C)</enum><text>by redesignating subparagraph (C) as subparagraph (B).</text> </subparagraph></paragraph></section><section id="id05847591B773467A82A316974AD3DFED"><enum>7.</enum><header>Priority review to encourage treatments for agents that present national security threats</header><text display-inline="no-display-inline">Subchapter E of chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb">21 U.S.C. 360bbb et seq.</external-xref>) is amended by inserting after section 565 the following:</text>
			<quoted-block display-inline="no-display-inline" id="id5B60A52EF9174254BF7234B10B39D2B3" style="OLC">
				<section id="idEF09926996134D1EB4E0EBEFF54A63FD"><enum>565A.</enum><header>Priority review to encourage treatments for agents that present national security threats</header>
 <subsection id="id188F7F26B15442AEB6F82ADC7C55007B"><enum>(a)</enum><header>Definitions</header><text>In this section:</text> <paragraph id="id112303b9652a425994d59b381e4540a9"><enum>(1)</enum><text>The term <term>priority review</term> with respect to a human drug application as defined in section 735(1), means review and action by the Secretary on such application not later than 6 months after receipt by the Secretary of such application, as described in the Manual of Policies and Procedures in the Food and Drug Administration and goals identified in the letters described in section 101(b) of the Food and Drug Administration Safety and Innovation Act.</text>
 </paragraph><paragraph id="id1adc0150107349d380b228b319cb627c"><enum>(2)</enum><header>Priority review voucher</header><text>The term <term>priority review voucher</term> means a voucher issued by the Secretary to the sponsor of a material threat medical countermeasure application that entitles the holder of such voucher to priority review of a single human drug application submitted under section 505(b)(1) or section 351 of the Public Health Service Act after the date of approval of the material threat medical countermeasure application.</text>
 </paragraph><paragraph id="id705fd237d76945a68a2e4b22562da14b"><enum>(3)</enum><header>Material threat medical countermeasure application</header><text>The term <term>material threat medical countermeasure application</term> means an application that—</text> <subparagraph id="idbea1dbe0daa9490282cdd16bdb6b8093"><enum>(A)</enum><text>is a human drug application as defined in section 735(1)—</text>
 <clause id="id710586c71e3d42418c04e7cb27df2df2"><enum>(i)</enum><text>to prevent, or treat harm from a biological, chemical, radiological, or nuclear agent identified as a material threat under section 319F–2(c)(2)(A)(ii) of the Public Health Service Act, or</text>
 </clause><clause id="ida49f276763ab480da1dcfbaac8697fcd"><enum>(ii)</enum><text>to mitigate, prevent, or treat harm from a condition that may result in adverse health consequences or death and may be caused by administering a drug, or biological product against such agent;</text>
 </clause></subparagraph><subparagraph id="id5b479a4fe1fd447c87feade758f4305c"><enum>(B)</enum><text>the Secretary deems eligible for priority review;</text> </subparagraph><subparagraph id="id8ad8d6414c76425d8c6796ac44124130"><enum>(C)</enum><text>is approved after the date of enactment of the <short-title>Medical Countermeasure Innovation Act of 2015</short-title>; and</text>
 </subparagraph><subparagraph id="id15F860F4E834481881C281218E6A6D5B"><enum>(D)</enum><text>is for a human drug, no active ingredient (including any ester or salt of the active ingredient) of which has been approved in any other application under section 505(b)(1) or section 351 of the Public Health Service Act.</text>
							</subparagraph></paragraph></subsection><subsection id="id237CEF8BAB994E88ABE8DD830A7EF5D9"><enum>(b)</enum><header>Priority review voucher</header>
 <paragraph id="id8436d03b54c8434b9efb0779d7fa4eb0"><enum>(1)</enum><header>In general</header><text>The Secretary shall award a priority review voucher to the sponsor of a material threat medical countermeasure application upon approval by the Secretary of such material threat medical countermeasure application.</text>
 </paragraph><paragraph id="id733e0a9868494101a40aeca7e72e82de"><enum>(2)</enum><header>Transferability</header><text>The sponsor of a material threat medical countermeasure application that receives a priority review voucher under this section may transfer (including by sale) the entitlement to such voucher to a sponsor of a human drug for which an application under section 505(b)(1) or section 351 of the Public Health Service Act will be submitted after the date of the approval of the material threat medical countermeasure application. There is no limit on the number of times a priority review voucher may be transferred before such voucher is used.</text>
						</paragraph><paragraph id="ida1f631853b2b4f5ab6588081b6df9b65"><enum>(3)</enum><header>Notification</header>
 <subparagraph id="idca9c0492237842169a938d3248238a63"><enum>(A)</enum><header>In general</header><text>The sponsor of a human drug application shall notify the Secretary not later than 90 calendar days prior to submission of the human drug application that is the subject of a priority review voucher of an intent to submit the human drug application, including the date on which the sponsor intends to submit the application. Such notification shall be a legally binding commitment to pay for the user fee to be assessed in accordance with this section.</text>
 </subparagraph><subparagraph id="idab6208dbb1aa4364ae991a3180967429"><enum>(B)</enum><header>Transfer after notice</header><text>The sponsor of a human drug application that provides notification of the intent of such sponsor to use the voucher for the human drug application under subparagraph (A) may transfer the voucher after such notification is provided, if such sponsor has not yet submitted the human drug application described in the notification.</text>
							</subparagraph></paragraph></subsection><subsection id="id42015ADD64304E6EB548485C7FD7323A"><enum>(c)</enum><header>Priority review user fee</header>
 <paragraph id="idCA71405B6EE148DEA7F8BA047AB3112F"><enum>(1)</enum><header>In general</header><text>The Secretary shall establish a user fee program under which a sponsor of a human drug application that is the subject of a priority review voucher shall pay to the Secretary a fee determined under paragraph (2). Such fee shall be in addition to any fee required to be submitted by the sponsor under chapter VII.</text>
 </paragraph><paragraph id="id0A488F49998243938658D7BBC03355EA"><enum>(2)</enum><header>Fee amount</header><text>The amount of the priority review user fee shall be determined each fiscal year by the Secretary and based on the average cost incurred by the agency in the review of a human drug application subject to priority review in the previous fiscal year.</text>
 </paragraph><paragraph id="id4B23901076CA4B549130280AF90BF3C9"><enum>(3)</enum><header>Annual fee setting</header><text>The Secretary shall establish, before the beginning of each fiscal year beginning after September 30, 2015, for that fiscal year, the amount of the priority review user fee.</text>
						</paragraph><paragraph id="id35DD3C1F9AA8409A8F1773A3139C82D1"><enum>(4)</enum><header>Payment</header>
 <subparagraph id="idB60F899AB2DE4EDC8DC7A79ED941B3E2"><enum>(A)</enum><header>In general</header><text>The priority review user fee required by this subsection shall be due upon the submission of a human drug application under section 505(b)(1) or section 351 of the Public Health Service Act for which the priority review voucher is used.</text>
 </subparagraph><subparagraph id="id420982A4E9A1454D94B7C68E95FEEB0A"><enum>(B)</enum><header>Complete application</header><text>An application described under subparagraph (A) for which the sponsor requests the use of a priority review voucher shall be considered incomplete if the fee required by this subsection and all other applicable user fees are not paid in accordance with the Secretary's procedures for paying such fees.</text>
 </subparagraph><subparagraph id="id3B2D242A35CA4B43B907A14CB6069B78"><enum>(C)</enum><header>No waivers, exemptions, reductions, or refunds</header><text>The Secretary may not grant a waiver, exemption, reduction, or refund of any fees due and payable under this section.</text>
 </subparagraph></paragraph><paragraph id="id16D0A0188A2141638195DBDD63935B7C"><enum>(5)</enum><header>Offsetting collections</header><text>Fees collected pursuant to this subsection for any fiscal year—</text> <subparagraph id="ID24C8BB824E994E13A4DF549A8BAF2603"><enum>(A)</enum><text>shall be deposited and credited as offsetting collections to the account providing appropriations to the Food and Drug Administration; and</text></subparagraph><subparagraph id="idCFFFD632FF0847BF892AADDCCDCAB732"><enum>(B)</enum><text>shall not be collected for any fiscal year except to the extent provided in advance in appropriation Acts.</text>
 </subparagraph></paragraph></subsection><subsection id="id0E532B6BD668426C95877D7128D69282"><enum>(d)</enum><header>Notice of Issuance of Voucher and Approval of Products Under Voucher</header><text>The Secretary shall publish a notice in the Federal Register and on the Internet Website of the Food and Drug Administration not later than 30 calendar days after the occurrence of each of the following:</text>
 <paragraph id="id4c3b4109688b46ba9fa03c5e9fcad797"><enum>(1)</enum><text>The Secretary issues a priority review voucher under this section.</text> </paragraph><paragraph id="id50f93b71b81e4f6185bad8444c9ccd5e"><enum>(2)</enum><text>The Secretary approves a drug pursuant to an application submitted under section 505(b) of this Act or section 351(a) of the Public Health Service Act for which the sponsor of the application used a priority review voucher under this section.</text>
 </paragraph></subsection><subsection id="id7DC6A13264A243DB9CD104B3017BB317"><enum>(e)</enum><header>Eligibility for other programs</header><text>Nothing in this section precludes a sponsor who seeks a priority review voucher under this section from participating in any other incentive program, including under this Act, except that no sponsor of a material threat medical countermeasure application may receive more than one priority review voucher with respect to such drug.</text>
 </subsection><subsection id="id5A6DD08EFD424718825E523790545321"><enum>(f)</enum><header>Relation to other provisions</header><text>The provisions of this section shall supplement, not supplant, any other provisions of this Act or the Public Health Service Act that encourage the development of medical countermeasures.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body>
</bill>


